Literature DB >> 27614591

Safety of Concurrent Boston Type I Keratoprosthesis and Glaucoma Drainage Device Implantation.

Tamara L Lenis1, Stephan Y Chiu1, Simon K Law1, Fei Yu2, Anthony J Aldave3.   

Abstract

PURPOSE: To evaluate the safety of concurrent Boston type I keratoprosthesis (KPro) and glaucoma drainage device (GDD) implantation.
DESIGN: Retrospective comparative study of a consecutive cohort of patients.
SUBJECTS: Patients who underwent KPro implantation by a single surgeon (A.J.A.) with or without 1 concurrent Ahmed GDD (New World Medical, Inc., Rancho Cucamonga, CA) implantation between January 1, 2005, and January 31, 2015, were included. Patients with fewer than 3 months of follow-up or a history of previous KPro implantation were excluded.
METHODS: Preoperative, operative, and postoperative data were collected for each procedure. All comparisons were made between KPro procedures performed with or without concurrent GDD implantation. The Fisher exact test (2-tailed) was used to compare proportions, Student t test and Wilcoxon rank-sum test were used to compare means, and the log-rank test was used to compare time-to-outcome events. MAIN OUTCOME MEASURES: The primary outcome was frequency of the composite variable, that is, any serious vision-threatening postoperative complication, which included sterile vitreitis, endophthalmitis, hypotony maculopathy, suprachoroidal hemorrhage, retinal detachment, stromal necrosis, and infectious keratitis. Secondary outcomes included intraocular pressure control, worsening of visual acuity, cystoid macular edema, retroprosthetic membrane formation, persistent epithelial defect formation, GDD exposure, and KPro removal.
RESULTS: One hundred thirty-seven KPro procedures were performed in 129 patients: 91 (66.4%) KPro alone and 46 (33.6%) KPro plus GDD. There were no statistically significant differences between the 2 groups in terms of the incidence of vision-threatening postoperative complications. None of the 46 GDDs placed at the same time as the KPro became exposed during an average follow-up of 44 months.
CONCLUSIONS: Compared with KPro alone, GDD placement combined with KPro was not associated with increased postoperative complications.
Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27614591     DOI: 10.1016/j.ophtha.2016.08.003

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

1.  Management of Congenital Aniridia-Associated Keratopathy: Long-Term Outcomes from a Tertiary Referral Center.

Authors:  Ghasem Yazdanpanah; Kelley J Bohm; Omar M Hassan; Faris I Karas; Abdelrahman M Elhusseiny; Manachai Nonpassopon; Muanploy Niparugs; Elmer Y Tu; Joel Sugar; Mark I Rosenblatt; Maria S Cortina; Ali R Djalilian
Journal:  Am J Ophthalmol       Date:  2019-11-12       Impact factor: 5.258

2.  Combined Corneal Transplant, Glaucoma Drainage Implantation, and Pars Plana Vitrectomy Outcomes in a Pediatric Population.

Authors:  Kelley J Bohm; Alvaro Fernandez-Vega; Luis Acaba-Berrocal; R V Paul Chan; M Soledad Cortina
Journal:  Cornea       Date:  2022-02-05       Impact factor: 3.152

3.  Five year outcomes of Boston type I keratoprosthesis as primary versus secondary penetrating corneal procedure in a matched case control study.

Authors:  Kai B Kang; Faris I Karas; Ruju Rai; Joelle A Hallak; Joann J Kang; Jose de la Cruz; Maria S Cortina
Journal:  PLoS One       Date:  2018-02-06       Impact factor: 3.240

4.  Resolution of an exposed pars plana Baerveldt shunt in a patient with a Boston keratoprosthesis type 1 without surgery.

Authors:  Daniel J Oh; Raman Michael; Thasarat Vajaranant; M Soledad Cortina; Ellen Shorter
Journal:  Ther Adv Ophthalmol       Date:  2019-08-12

Review 5.  Boston Type 1 Keratoprosthesis: Updated Perspectives.

Authors:  Manachai Nonpassopon; Muanploy Niparugs; Maria Soledad Cortina
Journal:  Clin Ophthalmol       Date:  2020-04-29

6.  Biocompatibility evaluation of bioprinted decellularized collagen sheet implanted in vivo cornea using swept-source optical coherence tomography.

Authors:  Jaeseok Park; Kyoung-Pil Lee; Hyeonji Kim; Sungjo Park; Ruchire E Wijesinghe; Jaeyul Lee; Sangyeob Han; Sangbong Lee; Pilun Kim; Dong-Woo Cho; Jinah Jang; Hong K Kim; Mansik Jeon; Jeehyun Kim
Journal:  J Biophotonics       Date:  2019-07-23       Impact factor: 3.207

Review 7.  Challenges of Glaucoma Management in Patients with Type I Boston Keratoprosthesis.

Authors:  Sara M AlHilali; Samar A Al-Swailem
Journal:  Clin Ophthalmol       Date:  2022-02-11

8.  Titanium Powder 3D-Printing Technology for a Novel Keratoprosthesis in Alkali-Burned Rabbits.

Authors:  Otavio de Azevedo Magalhães; Rafael Jorge Alves de Alcantara; José Alvaro Pereira Gomes; Jarbas Caiado de Castro Neto; Paulo Schor
Journal:  Transl Vis Sci Technol       Date:  2022-08-01       Impact factor: 3.048

9.  Vision retention in early versus delayed glaucoma surgical intervention in patients with Boston Keratoprosthesis type 1.

Authors:  Mark Lin; Anand Bhatt; Asghar Haider; Grace Kim; Marjan Farid; Mason Schmutz; Sameh Mosaed
Journal:  PLoS One       Date:  2017-08-04       Impact factor: 3.240

10.  Clinical Experience in Patients with Ocular Burns Treated with Boston Type I Keratoprosthesis Implantation with or Without Prophylactic Ahmed Glaucoma Valve Implantation.

Authors:  Jianjun Gu; Yuying Zhang; Jiajie Zhai; Lixia Lin; Zhancong Ou; Ting Huang; Miao Chen; Jin Zhou; Liangbo Zeng; Yuwei Xu; Jiaqi Chen
Journal:  Ophthalmol Ther       Date:  2021-12-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.